(DOMANE recommended Remdesivir for treatment of Covid-19 patients which killed many of them and DTRA made Covid-19 in the first place... and here we are setting up the blame for the NEXT ONE on China)
from DVids
The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological
Technologies Department, in its role as the Joint Science and Technology
Office (JSTO), is developing a system-of-systems called DOMANE —
Discovery of MCMs (medical countermeasures) Against Novel Entities — an
interdisciplinary effort with team members whose expertise include
computer science, physics, and medicine. DTRA CB posits that one drug
may be insufficient towards countering a threat, so it is developing
DOMANE to rapidly identify a combination of drugs to impact the novel
biological threat from multiple targets, which may prove effective in
promoting a disease-modifying effect to counter the biological threat.
Systems within DOMANE include machine learning, high-throughput
screening, in silico predictive tools, cryogenic electron microscopy
(cryo-EM), organ-on-a-chip, and other emergent technologies.
Machine-learning algorithms greatly reduce the time needed to search
vast amounts of data on drugs and diseases. DOMANE is possible, in part,
because of research studies that have occurred over the past several
decades on biological threat agents and MCMs. The studies resulted in
the global availability of a large repository of laboratory and clinical
data (“big data”) on how biological threats affect the human body.
The COVID-19 pandemic and the resulting national human and economic toll
demonstrate a clear and present vulnerability of the U.S. to emerging
and unknown contagious infectious diseases. For Joint Forces on the
battlefield, the possibility of illness due to emerging biological
threats can impact their mission. Ideally, they should be equipped with
the MCMs they need to lessen the influence of emerging biological
threats.
DOMANE started in (late) 2019, (right) before the current pandemic, with the goal to
shorten the traditional, multi-year timeline for developing MCMs to
treat novel diseases. Utilizing drugs already approved by the Food and
Drug Administration (FDA), DOMANE will evaluate the feasibility of
repurposing them as MCMs to combat emerging threats. Some of the
advantages to using FDA-approved drugs are that they are already
manufacturable, have well-known toxicological profiles, and can proceed
directly to human efficacy or Animal Rule studies. This can reduce or
eliminate the time-intensive animal toxicology and human safety studies
and enhance current good manufacturing practice to scale up process and
ongoing stability assessment...
read more here
